Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

D. Hellmann, Matthew; Paz‐Ares, Luis; Bernabe Caro, Reyes; Żurawski, Bogdan; Kim, Sang‐We; Carcereny, Enric; Park, Keunchil; Alexandru, Aurelia; Lupinacci, Lorena; de la Mora Jimenez, Emmanuel; Sakai, Hiroshi; Albert, István; Vergnenègre, A.; Peters, Solange; Syrigos, Konstantinos; Barlési, Fabrice; Reck, Martin; Borghaei, Hossein; R. Brahmer, Julie; J. O’Byrne, Kenneth; J. Geese, William; Bhagavatheeswaran, Prabhu; K. Rabindran, Sridhar; S. Kasinathan, Ravi; E. Nathan, Faith; S. Ramalingam, Suresh

doi:10.1056/nejmoa1910231

Public

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Sep 28, 2019

Authors:

Matthew D. Hellmann

Luis Paz‐Ares

Reyes Bernabe Caro

Abstract

BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are nee...

Subject

Nivolumab

Ipilimumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!